799 Randomized trial of docetaxel plus clsplatin (DC) versus etoposide plus cisplatin (EC) in locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

H.S.Park; S.J.Lee; J.H.Kim; M.J.Ahn; J.A.Lee; C.Y.Yim; C.S.Kim; S.Mun; Y.S.Lee

首页> 外文期刊>European Journal of Cancer Supplements >799 Randomized trial of docetaxel plus clsplatin (DC) versus etoposide plus cisplatin (EC) in locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

【24h】

799 Randomized trial of docetaxel plus clsplatin (DC) versus etoposide plus cisplatin (EC) in locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

机译：799多西紫杉醇联合克铂（DC）与依托泊苷联合顺铂（EC）在局部晚期，复发或转移性非小细胞肺癌（NSCLC）中的随机试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共1页
作者
H.S.Park; S.J.Lee; J.H.Kim; M.J.Ahn; J.A.Lee; C.Y.Yim; C.S.Kim; S.Mun; Y.S.Lee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. [J] . Kim JH, Kim SY, Jung KH, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2006,第1期

机译：吉西他滨联合顺铂与依托泊苷联合顺铂治疗局部晚期或转移性非小细胞肺癌的随机II期研究：韩国癌症研究小组的经验。
2. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial [J] . Stefano Kim, Bruno Buecher, Thierry André, BMC Cancer . 2020,第1期

机译：atezolizumab加修饰的多西紫杉醇 - 顺铂-5-氟尿嘧啶（MDCF）方案与MDCF在转移或不可切除的局部晚期复发性肛鳞细胞癌中的患者：随机的非比较期II稀缺的Gercor试验
3. 6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC) [J] . J.Rolski, T.Grodzki, C.P.Schneider, European Journal of Cancer Supplements . 2007,第4期

机译：6501 ORAL全球肺肿瘤科试验3（GLOB 3）：一项针对口服和静脉注射的跨国多国III期随机试验的生活质量（QoL）结果。长春瑞滨（NVB）加顺铂（CDDP）与多西他赛（DTX）加CDDP作为晚期非小细胞肺癌（NSCLC）的一线治疗
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized non-comparative phase II SCARCE GERCOR trial [O] . Stefano Kim, Bruno Buecher, Thierry André, 2020

机译：Atezolizumab联合改良多西他赛-顺铂-5-氟尿嘧啶（mDCF）方案与mDCF在转移性或不可切除的局部晚期复发性肛门鳞状细胞癌患者中的比较：一项随机非对照II期SCARCE GERCOR试验
7. P2-291: Results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC) [O] . Novello Silvia, Tibaldi Carmelo, Scagliotti Giorgio V., 2007

机译：P2-291：一项多中心紫杉醇（D）和吉西他滨（G）和顺铂/吉西他滨（CG）两种不同组合的多中心随机II期试验的结果，然后多西紫杉醇作为局部晚期或转移性非小细胞肺癌的一线治疗癌症（NSCLC）

799 Randomized trial of docetaxel plus clsplatin (DC) versus etoposide plus cisplatin (EC) in locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅